The U.S. Food and Drug Administration has approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older, Alvotech (ALVO) and Teva Pharmaceuticals said in a statement.
ALVO closed Tuesday's regular trading at $12.73 up $0.23 or 1.84%. In the after-hours trading the stock further gained $1.66 or 13.04%.
Under the strategic partnership between Teva and Alvotech, Teva is responsible for the exclusive commercialization of Selarsdi in the United States.
Selarsdi is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of Stelara.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.